Invention Grant
- Patent Title: Immunomodulators acting as antagonists of PD-1
-
Application No.: US16624989Application Date: 2018-06-21
-
Publication No.: US11066445B2Publication Date: 2021-07-20
- Inventor: Kevin W. Gillman , Jason Goodrich , Li-Qiang Sun , Eric Mull , David R. Langley , Paul Michael Scola
- Applicant: Bristol-Myers Squibb Company
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agency: Sterne, Kessler, Goldstein, Fox P.L.L.C.
- International Application: PCT/US2018/038768 WO 20180621
- International Announcement: WO2018/237153 WO 20181227
- Main IPC: C07K7/56
- IPC: C07K7/56 ; A61K38/00
Abstract:
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Public/Granted literature
- US20200172578A1 IMMUNOMODULATORS ACTING AS ANTAGONISTS OF PD-1 Public/Granted day:2020-06-04
Information query
